Tests experimental bispecific antibody drugs in lupus nephritis
Tests two experimental drugs for kidney inflammation caused by lupus in adults.
Plain-language title generated from the registry record
Registry title: Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Key facts
- Where
- Mainz and Regensburg, GermanySee the 2 sites
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with lupus nephritis (kidney disease caused by lupus) whose disease did not respond to treatment or came back.
- Age
- 18 to 60 years
- Sex
- Men and women can join.
- Disease stage
- Systemic lupus erythematosus (SLE) with lupus nephritis, refractory (not responding to treatment) or relapsed (came back), as described in the protocol.
Main reasons for not taking part
- Severe or unstable lupus-related brain or mental illness likely to need urgent treatment or hospital care
- Active overlap syndrome with mixed connective tissue disease or systemic sclerosis within 12 months before screening or during screening
- Catastrophic or severe antiphospholipid syndrome within 12 months before screening or during screening
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT06975787, who can take part
Where in Germany
- Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöRMainz, GermanyTaking people
- Universitaetsklinikum Regensburg AöRRegensburg, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Regeneron Pharmaceuticals
- Trial code
- NCT06975787EU 2024-518288-37-00
- Record updated
- 27 October 2026
- Original description
This study is researching a particular group of experimental drugs administered for a short period in the treatment of participants with Lupus Nephritis (LN).Read full original descriptionShow less
A Dose Escalation Study Investigating Bispecific Antibody Therapy in Patients With Lupus Nephritis
This study is researching a particular group of experimental drugs administered for a short period in the treatment of participants with Lupus Nephritis (LN).
The main aim of the current study is to see how safe and tolerable the study drugs are in a long-term follow-up.
This is a main study, called an umbrella study, which includes several independent smaller sub-studies. Each of these smaller main sub-studies tests different drugs at the same time, all aimed at treating LN.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Key General Inclusion Criteria:; Diagnosis of Systemic Lupus Erythematosus (SLE) and LN, as described in the protocol; Participant must have refractory or relapsed disease, as described in the protocol; Key General Exclusion Criteria:; History of or active severe or unstable lupus-associated neuropsychiatric disease that is likely to require acute or emergent medical treatment or hospitalization; Active overlap syndrome with mixed connective tissue disease or systemic sclerosis within 12 months prior to screening or during screening; Catastrophic or severe antiphospholipid syndrome within 12 months prior to screening or during screening; NOTE: Other protocol defined inclusion/exclusion criteria apply.